The New England journal of medicine, 2022-03, Vol.386 (12), p.1143-1154
- Cortés, Javier
- Kim, Sung-Bae
- Chung, Wei-Pang
- Im, Seock-Ah
- Park, Yeon Hee
- Hegg, Roberto
- Kim, Min Hwan
- Tseng, Ling-Ming
- Petry, Vanessa
- Chung, Chi-Feng
- Iwata, Hiroji
- Hamilton, Erika
- Curigliano, Giuseppe
- Xu, Binghe
- Huang, Chiun-Sheng
- Kim, Jee Hyun
- Chiu, Joanne W.Y
- Pedrini, Jose Luiz
- Lee, Caleb
- Liu, Yali
- Cathcart, Jillian
- Bako, Emarjola
- Verma, Sunil
- Hurvitz, Sara A
2022
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Cortés, Javier
- Kim, Sung-Bae
- Chung, Wei-Pang
- Im, Seock-Ah
- Park, Yeon Hee
- Hegg, Roberto
- Kim, Min Hwan
- Tseng, Ling-Ming
- Petry, Vanessa
- Chung, Chi-Feng
- Iwata, Hiroji
- Hamilton, Erika
- Curigliano, Giuseppe
- Xu, Binghe
- Huang, Chiun-Sheng
- Kim, Jee Hyun
- Chiu, Joanne W.Y
- Pedrini, Jose Luiz
- Lee, Caleb
- Liu, Yali
- Cathcart, Jillian
- Bako, Emarjola
- Verma, Sunil
- Hurvitz, Sara A
- Titel
- Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
- Ist Teil von
- The New England journal of medicine, 2022-03, Vol.386 (12), p.1143-1154
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2022
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- In patients with metastatic HER2-positive breast cancer that had progressed after primary therapy, treatment with the antibody–drug conjugate trastuzumab deruxtecan resulted in a higher response rate and longer progression-free survival than trastuzumab emtansine. Since trastuzumab deruxtecan was associated with interstitial pulmonary fibrosis, close monitoring of pulmonary function is warranted.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa2115022Titel-ID: cdi_proquest_miscellaneous_2642885311
- Format
- –
- Schlagworte
- Ado-Trastuzumab Emtansine - adverse effects, Ado-Trastuzumab Emtansine - therapeutic use, Adult, Adverse events, Aged, Aged, 80 and over, Antibodies, Antineoplastic Agents, Immunological - adverse effects, Antineoplastic Agents, Immunological - therapeutic use, Breast Cancer, Breast Neoplasms - drug therapy, Breast Neoplasms - mortality, Breast Neoplasms - pathology, Camptothecin - adverse effects, Camptothecin - analogs & derivatives, Camptothecin - therapeutic use, Cytotoxicity, Death, Drug dosages, Epidermal growth factor, ErbB-2 protein, Female, Hematology, Humans, Immunoconjugates - adverse effects, Immunoconjugates - therapeutic use, Kaplan-Meier Estimate, Lung diseases, Lung Diseases, Interstitial - chemically induced, Metastases, Metastasis, Middle Aged, Monoclonal antibodies, Oncology, Patients, Pneumonia - chemically induced, Pneumonitis, Progression-Free Survival, Receptor, ErbB-2 - antagonists & inhibitors, Receptor, ErbB-2 - metabolism, Risk assessment, Statistical analysis, Survival, Targeted cancer therapy, Taxanes, Trastuzumab, Trastuzumab - adverse effects, Trastuzumab - therapeutic use, Treatments in Oncology